Table I.

Experimental intestinal anaphylaxis in iFABPp-IL-9Tg mice is IL-4Rα and STAT6 dependent

Experimental group
Treatment
% Diarrhea occurrence (on day 9)
Mast cells/HPF (mean ± SEM)
Serum mMCP-1 (ng/ml; mean ± SEM)
BALB/c WT    0.68 ± 0.07 27.46 ± 3.90 
    BALB/c WT Vehicle OVA 0/12 0.13 ± 0.01 23.91 ± 3.64 
    BALB/c WT OVA OVA 14/14 31.29 ± 0.57 16,260.57 ± 4,817.16 
IFABPp-IL-9Tg    7.20 ± 0.33 152.50 ± 1.65 
    IFABPp-IL-9Tg Vehicle OVA 15/15 28.68 ± 0.82 19,319.34 ± 3,961.13 
    IFABPp-IL-9Tg OVA OVA 12/16 97.52 ± 2.19 83,399.48 ± 7,880.93 
IFABPp-IL-9Tg (IL-9Tg)/ STAT6−/−    2.87 ± 0.31 37.90 ± 1.60 
    IL-9Tg/STAT6−/− Vehicle OVA 0/9 2.93 ± 0.21 870.30 ± 191.92 
    IL-9Tg/STAT6−/− OVA OVA 1/8 11.91 ± 0.66 1,168.17 ± 268.46 
IFABPp-IL-9Tg (IL-9Tg)/IL-4Rα−/−    2.75 ± 0.01 26.20 ± 0.90 
    IL-9Tg/IL-4Rα−/− Vehicle OVA 0/10 3.04 ± 0.14 100.26 ± 15.01 
    IL-9Tg/IL-4Rα−/− OVA OVA 0/9 8.05 ± 0.19 808.07 ± 154.09 

Diarrhea, mean number of mast cells per high power field of view and serum mMCP-1 for iFABPp-IL-9Tg and BALB/c WT mice deficient in IL-4Rα or STAT6 following intraperitoneal sensitization with OVA or saline and nine intragastric OVA or saline challenges.

[ViewLarge]
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal